Comparative Pharmacology
Head-to-head clinical analysis: PROMPT PHENYTOIN SODIUM versus VIMPAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMPT PHENYTOIN SODIUM versus VIMPAT.
PROMPT PHENYTOIN SODIUM vs VIMPAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
Selective enhancement of slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
Adults: 200 mg oral or IV as a loading dose, followed by 100 mg twice daily (200 mg/day) starting the day after loading. May increase by 50 mg twice daily every week up to 200 mg twice daily (400 mg/day).
None Documented
None Documented
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Terminal half-life: 13-16 hours (mean ~13 h at steady state); prolonged with renal impairment (CrCl <30 mL/min: ~22 h) and in patients with hepatic impairment (Child-Pugh B: ~17 h; Child-Pugh C: ~22 h).
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Renal: ~95% (40% as parent drug, 39% as O-desmethyl metabolite, and ~15% as other minor metabolites); minimal biliary/fecal elimination (less than 1%).
Category D/X
Category C
Anticonvulsant
Anticonvulsant